Rhythm Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity.The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency.
